1. Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
   Bashir Lawal et al, 2021, Biomedicines CrossRef
2. Transcriptomic profiling of Indian breast cancer patients revealed subtype-specific mRNA and lncRNA signatures
   Meghana Manjunath et al, 2022, Frontiers in Genetics CrossRef
3. Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors
   Nawal Bendris et al, 2015, Cell Cycle CrossRef
4. Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies
   Bashir Lawal et al, 2021, Cancers CrossRef
5. CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity
   Ruiying Zhao et al, 2013, Cell Cycle CrossRef
6. SDF-1/CXCR4 signal is involved in decreased expression ofp57kip2inde novoMDS patients
   Youshan Zhao et al, 2012, Hematology CrossRef
7. Fbxo22 promotes cervical cancer progression via targeting p57Kip2 for ubiquitination and degradation
   Min Lin et al, 2022, Cell Death & Disease CrossRef
8. The role of cytoplasmic p57 in invasion of hepatocellular carcinoma
   Hui Guo et al, 2015, BMC Gastroenterology CrossRef
9. Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype
   E C Maggi et al, 2016, Oncogenesis CrossRef
10. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
    Jessica N. Spradlin et al, 2019, Nature Chemical Biology CrossRef